MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2018 International Congress

    What is the relationship between dyskinesia and performance of activities of daily living in patients with Parkinson’s disease?

    E. Goubault, S. Bogard, K. Lebel, C. Duval (Montreal, QC, Canada)

    Objective: The aim of this study was to determine which of drug-induced dyskinesia (DID) or other symptoms of Parkinson's disease (PD) had the most impact…
  • 2018 International Congress

    Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry

    D. Johansson, A. Ericsson, A. Johansson, A. Medvedev, D. Nyholm, F. Ohlsson, M. Senek, J. Spira, I. Thomas, J. Westin, F. Bergquist (Gothenburg, Sweden)

    Objective: This four-week open-label observational study describes the effect of introducing a microtablet dose dispenser and adjusting doses based on objective free-living motor symptom monitoring…
  • 2018 International Congress

    Chronological view of peak and diphasic dyskinesia, wearing off and freezing in Parkinson’s disease: 1212 Korean population

    Y.E. Kim, B. Jeon. (Anyang, Republic of Korea)

    Objective: To evaluate the gross chronological trend of 4 motor complications - peak dose dyskinesia, diphasic dyskinesia, wearing off and freezing. Background: Dyskinesia, wearing off…
  • 2018 International Congress

    Differences in the Unified Dyskinesia Rating Scale based on age, Parkinson´s Disease and Dyskinesias duration

    E. Cubo, S. Luo, S. Calvo, P. Martinez-Martín (Burgos, Spain)

    Objective: To analyze the Unified Dyskinesia Rating Scale (UDysRS) scores on Historical, Objective parts and their differences based on age, Parkinson´s disease (PD) and dyskinesias…
  • 2018 International Congress

    Clinical practice of levodopa in parkinsonism

    AC. Chen (Taichung, Taiwan)

    Objective: This study is for the clinical effect of levodopa in parkinsonism. Background: Levodopa was common used in Parkinson disease. Levodopa induced dyskinesia(LID) is the…
  • 2018 International Congress

    Levodopa induced dyskinesia is preventable (15 years experience using continuous dopaminergic stimulation)

    M. Lin, R. Laureno (Washington, DC, USA)

    Objective: To evaluate whether levodopa induced dyskinesia is preventable in the treatment of patients with Parkinson’s disease. Background: Dyskinesia is one of the major complications…
  • 2018 International Congress

    Retrospective study on a cohort of 285 PD patients: Does the side of onset influence the global clinical phenotype?

    G. Lazzeri, G. Franco, E. Monfrini, E. Frattini, I. Trezzi, L. Borellini, G. Ardolino, F. Cogiamanian, A. Di Fonzo (Milano, Italy)

    Objective: To describe demographic and clinical characteristics of a cohort of 285 consecutive PD patients and to understand the phenotypic differences of right onset (RPD)…
  • 2018 International Congress

    Lycopene ameliorates haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation

    S. Jamwal, P. Kumar (Baddi, India)

    Objective: The study was undertakento investigate the role of striatal neurotransmitters and neuroinflammatory cytokines in the neuroprotective effect of lycopene against haloperidol induced orofacial dyskinesia…
  • 2018 International Congress

    The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

    I. Frouni, D. Bedard, S. Belliveau, E. Bourgeois-Cayer, A. Hamadjida, P. Huot (Montreal, QC, Canada)

    Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…
  • 2018 International Congress

    The BlueSky Project: monitoring motor and non-motor characteristics of people with Parkinson’s disease in the laboratory, a simulated apartment, and home and community settings

    K. Erb, J. Daneault, S. Amato, P. Bergethon, C. Demanuele, T. Kangarloo, S. Patel, V. Ramos, D. Volfson, P. Wacnik, H. Zhang, D. Karlin, H. Huggins, L. Soll, G. Costante, G. Vergara-Diaz, F. Parisi, J. Banghu, C. Brooks, C. Dethridge, A. Abrami, E. Bilal, V. Caravagio, S. Heisig, R. Norel, E. Pissadaki, J. Rice, B. Ho, K. Thomas, P. Bonato (Cambridge, MA, USA)

    Objective: We present data collected for the BlueSky Project which aims to develop novel assessments of motor and non-motor function using mobile and wearable technology.…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley